Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (47 quarters reported)
$148M in Q4 2014 → $143M now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| PP Praxis Precision Medicines I | 19.3% | Trimmed 2.5% | 82,796 | $27.7M |
| Whitehawk Therapeutics Inc | 15.0% | Added 37% | 4,685,912 | $21.5M |
| Tango Therapeutics Inc | 8.5% | Trimmed 12% | 390,949 | $12.2M |
| Sutro Biopharma Inc | 6.3% | Added 0.3% | 270,251 | $8.97M |
| Arrivent Biopharma Inc | 5.3% | New | 218,694 | $7.6M |
| 4d Molecular Therapeutics Inc | 4.7% | New | 507,801 | $6.75M |
| Bright Minds Biosciences Inc | 4.5% | Trimmed 17% | 92,745 | $6.51M |
| Ocular Therapeutix Inc | 3.6% | Trimmed 10% | 532,481 | $5.23M |
| Erasca Inc | 3.4% | Trimmed 25% | 265,199 | $4.86M |
| Surrozen Inc | 3.1% | Added 0.3% | 173,395 | $4.5M |
| AS Argen Se - ADR | 3.0% | Added 0.3% | 4,705 | $4.37M |
| Moonlake Immunotherapeutics | 2.9% | Added 12% | 215,652 | $4.2M |
| Design Therapeutics Inc | 2.8% | Added 94% | 282,564 | $4.09M |
| Minerva Neurosciences | 2.7% | Unchanged | 709,500 | $3.94M |
| Taysha Gene Therapies Inc | 2.7% | Added 28% | 561,808 | $3.83M |
| Avalyn Pharma Inc | 2.6% | New | 115,000 | $3.79M |
| Avalo Therapeutics Inc | 2.4% | Added 206% | 186,308 | $3.44M |
| Amylyx Pharmaceuticals Inc | 2.1% | Added 11% | 168,115 | $3.02M |
| Artiva Biotherapeutics Inc | 1.8% | New | 260,416 | $2.53M |
| Compass Therapeutics Inc | 0.9% | Trimmed 30% | 595,213 | $1.3M |
| United Therapeutics Corp | 0.8% | Unchanged | 2,224 | $1.21M |
| CT Contineum Therapeutics Inc-a | 0.7% | New | 63,095 | $1.03M |
| Lb Pharmaceuticals Inc | 0.7% | Unchanged | 28,919 | $939K |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended June 30, 2026 · filed August 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Terns Pharmaceuticals Inc | Exited | −495,772 | −$26.1M | — |
| Arrivent Biopharma Inc | New | +218,694 | +$7.6M | 5.3% |
| 4d Molecular Therapeutics Inc | New | +507,801 | +$6.75M | 4.7% |
| Whitehawk Therapeutics Inc | Added | +1,275,510 | +$5.84M | 15.0% |
| Avalyn Pharma Inc | New | +115,000 | +$3.79M | 2.6% |
| Oculis Holding Ag | Exited | −98,339 | −$2.61M | — |
| Revolution Medicines Inc | Exited | −26,069 | −$2.54M | — |
| Artiva Biotherapeutics Inc | New | +260,416 | +$2.53M | 1.8% |
| Avalo Therapeutics Inc | Added | +125,500 | +$2.32M | 2.4% |
| 4d Molecular Therapeutics Inc | Exited | −242,255 | −$2.26M | — |
Showing the 10 largest of 29 changes.
quarter ended March 31, 2026 · filed May 15, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Cidara Therapeutics Inc | Exited | −89,145 | −$19.7M | — |
| Terns Pharmaceuticals Inc | Trimmed | −141,323 | −$7.45M | 18.4% |
| Erasca Inc | New | +354,575 | +$5.74M | 4.0% |
| Sutro Biopharma Inc | Added | +201,974 | +$5.03M | 4.7% |
| Jazz Pharmaceuticals PLC | Exited | −29,008 | −$4.93M | — |
| Insmed Inc | Exited | −25,878 | −$4.5M | — |
| Ocular Therapeutix Inc | Trimmed | −460,887 | −$3.9M | 3.5% |
| Tango Therapeutics Inc | Added | +159,099 | +$3.33M | 6.5% |
| Amylyx Pharmaceuticals Inc | Trimmed | −182,191 | −$2.53M | 1.5% |
| Moonlake Immunotherapeutics | Added | +132,480 | +$2.47M | 2.5% |
Showing the 10 largest of 34 changes.
quarter ended December 31, 2025 · filed February 17, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Tourmaline Bio Inc | Exited | −268,451 | −$12.8M | — |
| Cidara Therapeutics Inc | Trimmed | −52,384 | −$11.6M | 13.4% |
| PP Praxis Precision Medicines I | Added | +33,285 | +$9.81M | 16.6% |
| Terns Pharmaceuticals Inc | Added | +134,298 | +$5.43M | 17.5% |
| Minerva Neurosciences | New | +709,500 | +$2.85M | 1.9% |
| Tango Therapeutics Inc | New | +282,732 | +$2.51M | 1.7% |
| Insmed Inc | Trimmed | −12,714 | −$2.21M | 3.1% |
| AP Ascendis Pha-adr | Exited | −9,792 | −$1.95M | — |
| Krystal Biotech Inc | Exited | −10,573 | −$1.87M | — |
| Cogent Biosciences Inc | Exited | −102,907 | −$1.48M | — |
Showing the 10 largest of 22 changes.
quarter ended September 30, 2025 · filed November 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Soleno Therapeutics Inc | Exited | −63,436 | −$5.31M | — |
| Amylyx Pharmaceuticals Inc | New | +333,258 | +$4.53M | 4.7% |
| Cidara Therapeutics Inc | Trimmed | −38,040 | −$3.64M | 14.0% |
| Compass Therapeutics Inc | New | +840,090 | +$2.94M | 3.0% |
| Trevi Therapeutics Inc | Exited | −493,735 | −$2.7M | — |
| AP Ascendis Pha-adr | Trimmed | −12,784 | −$2.54M | 2.0% |
| Bright Minds Biosciences Inc | Added | +36,401 | +$2.21M | 5.3% |
| Revolution Medicines Inc | Trimmed | −47,282 | −$2.21M | 0.4% |
| HA Helix Acquisition Corp Ii | Exited | −187,257 | −$1.99M | — |
| Krystal Biotech Inc | New | +10,573 | +$1.87M | 1.9% |
Showing the 10 largest of 34 changes.
quarter ended June 30, 2025 · filed August 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Insmed Inc | Trimmed | −69,004 | −$6.94M | 5.2% |
| Enliven Therapeutics Inc | Exited | −265,269 | −$5.22M | — |
| Cidara Therapeutics Inc | Added | +53,861 | +$2.62M | 12.2% |
| Tourmaline Bio Inc | Trimmed | −143,200 | −$2.29M | 6.3% |
| Merck & Co | Exited | −22,994 | −$2.06M | — |
| Ocular Therapeutix Inc | Trimmed | −204,784 | −$1.9M | 13.1% |
| Edgewise Therapeutics Inc | Exited | −85,454 | −$1.88M | — |
| MB Mereo Biopharma Group Pl-adr | Exited | −791,815 | −$1.78M | — |
| Jazz Pharmaceuticals PLC | Added | +16,708 | +$1.77M | 3.9% |
| Trevi Therapeutics Inc | Trimmed | −292,226 | −$1.6M | 3.8% |
Showing the 10 largest of 33 changes.
quarter ended March 31, 2025 · filed May 15, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| CP Crinetics Pharmaceuticals In | Exited | −122,900 | −$6.28M | — |
| Soleno Therapeutics Inc | New | +67,136 | +$4.8M | 5.6% |
| Vaxcyte Inc | Exited | −45,000 | −$3.68M | — |
| Whitehawk Therapeutics Inc | Added | +1,561,000 | +$2.78M | 7.0% |
| Oculis Holding Ag | New | +125,000 | +$2.38M | 2.8% |
| Merck & Co | New | +22,994 | +$2.06M | 2.4% |
| Surrozen Inc | New | +170,000 | +$1.98M | 2.3% |
| Mersana Therapeutics Inc | Exited | −1,120,500 | −$1.6M | — |
| Revolution Medicines Inc | Trimmed | −45,038 | −$1.59M | 2.7% |
| Cidara Therapeutics Inc | Added | +71,235 | +$1.53M | 3.1% |
Showing the 10 largest of 44 changes.
quarter ended December 31, 2024 · filed February 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Vaxcyte Inc | Trimmed | −90,400 | −$7.4M | 3.7% |
| Arcellx Inc | Trimmed | −51,357 | −$3.94M | 0.8% |
| KO Kura Oncology Inc. Common Stock | Exited | −197,000 | −$3.85M | — |
| Bright Minds Biosciences Inc | New | +69,124 | +$2.49M | 2.5% |
| Compass Pathways PLC | Exited | −386,500 | −$2.43M | — |
| Taysha Gene Therapies Inc | Trimmed | −1,234,748 | −$2.14M | 1.5% |
| Trevi Therapeutics Inc | Added | +481,458 | +$1.98M | 3.2% |
| Acelyrin Inc | Exited | −364,000 | −$1.79M | — |
| MB Mereo Biopharma Group Pl-adr | Trimmed | −481,392 | −$1.68M | 2.7% |
| Dyne Therapeutics Inc | Exited | −46,200 | −$1.66M | — |
Showing the 10 largest of 45 changes.
quarter ended September 30, 2024 · filed November 14, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Ocular Therapeutix Inc | Trimmed | −1,581,059 | −$13.8M | 8.4% |
| PP Praxis Precision Medicines I | Trimmed | −106,931 | −$6.15M | 2.7% |
| Dyne Therapeutics Inc | Trimmed | −166,300 | −$5.97M | 1.3% |
| Sarepta Therapeutics Inc | Exited | −27,500 | −$4.35M | — |
| AP Agios Pharma | Exited | −78,700 | −$3.39M | — |
| Ascendis Pharma A/s | New | +21,000 | +$3.14M | 2.5% |
| Vaxcyte Inc | Added | +25,000 | +$2.86M | 12.5% |
| Viridian Therapeutics Inc | Exited | −199,433 | −$2.59M | — |
| Enliven Therapeutics Inc | Trimmed | −101,330 | −$2.59M | 6.1% |
| Insmed Inc | Added | +35,400 | +$2.58M | 6.4% |
Showing the 10 largest of 47 changes.
Loading...
